US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings

0.8708

-0.0129-1.46%

Volume:223.27K

Turnover:194.51K

Market Cap:171.29M

PE:-4.57

High:0.8827

Open:0.8823

Low:0.8601

Close:0.8837

52wk High:3.09

52wk Low:0.2556

Shares:196.71M

Float Shares:19.54M

Volume Ratio:0.33

T/O Rate:1.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1906

EPS(LYR):-0.0700

ROE:--

ROA:-515.37%

PB:-9.37

PE(LYR):-12.43

Loading ...

Overview Company News Filings

Tevogen Bio Holdings Inc.'s CIO to Join Panel at Databricks DATA + AI World Tour in Boston

Tevogen Cio and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks Data + AI World Tour in Boston

THOMSON REUTERS

Tevogen Bio Holdings Inc - Tvgn 116 Cumulative 5-Year Top-Line Revenue Forecast Is Estimated to Be About $6.5 Billion

THOMSON REUTERS

Tevogen Bio Projects $6.5 Billion in Revenue Over 5 Years for Liver Cancer Prevention Product, TVGN 116

Tevogen Bio Holdings Inc - Values Tvgn-489 at $9-$11 Bln Risk-Adjusted Net Present Value

THOMSON REUTERS

Tevogen Bio Announces $9-11 Billion Valuation for TVGN-489, Highlighting Promising Phase I Clinical Trial Results for COVID-19 Treatment

Tevogen Bio Projects $3.5 Billion Revenue Over 5 Years, Highlights $250 Million rNPV for Key Asset TVGN 930

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

Tevogen Bio Announces Promising Clinical Trial Results for TVGN 489, Aiming to Enhance COVID-19 Immunotherapy for Vulnerable Populations

Tevogen Bio Holdings: Enters Into Agreement for up to $50 Mln in Financing to Advance R&D and Clinical Development Efforts

THOMSON REUTERS

Press Release: REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

BRIEF-Tevogen Bio Holdings Anticipates Revenue By End Of 2026

Tevogen Bio Holdings Inc - Anticipates Revenue by End of 2026

THOMSON REUTERS

Tevogen Bio Holdings Reports Reduced Q2 2025 Net Loss of $5.5M, Down from $9.7M in Q2 2024, as Operating Efficiency Improves

Press Release: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Press Release: Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Press Release: Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":0.8708,"timestamp":1757706225873,"preClose":0.8837,"halted":0,"volume":223273,"delay":0,"floatShares":19535200,"shares":196705067,"eps":-0.190556,"marketStatus":"Trading","change":-0.0129,"latestTime":"09-12 15:44:26 EDT","open":0.8823,"high":0.8827,"low":0.8601,"amount":194505.5019515,"amplitude":0.025574,"askPrice":0.8729,"askSize":1200,"bidPrice":0.8652,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.190556,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1757707200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.8837,"preHourTrading":{"tag":"盘前","latestPrice":0.8801,"preClose":0.8837,"latestTime":"09:24 EDT","volume":4594,"amount":4044.41027042,"timestamp":1757683478467},"postHourTrading":{"tag":"盘后","latestPrice":0.8899,"preClose":0.8837,"latestTime":"19:59 EDT","volume":6389,"amount":5663.0179,"timestamp":1757635160433},"volumeRatio":0.332331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGN\",,,,,undefined,":{"symbol":"TVGN","floatShares":19535200,"roa":"-515.37%","roe":"--","lyrEps":-0.070045,"volumeRatio":0.332331,"shares":196705067,"dividePrice":0,"high":0.8827,"amplitude":0.025574,"preClose":0.8837,"low":0.8601,"week52Low":0.2556,"pbRate":"-9.37","week52High":3.09,"institutionHeld":0,"latestPrice":0.8708,"committee":-0.998335,"eps":-0.190556,"divideRate":0,"volume":223273,"delay":0,"ttmEps":-0.190556,"open":0.8823,"prevYearClose":1.03,"prevWeekClose":0.8664,"prevMonthClose":0.91,"prevQuarterClose":1.25,"fiveDayClose":0.8664,"twentyDayClose":0.98,"sixtyDayClose":1.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"TVGN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-05-14","symbol":"TVGN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-02-15","symbol":"TVGN","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741752000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVGN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVGN","date":"2025-09-11","current":-5.500839,"percent":0.905149,"low":-87.683882,"twenty":-29.856904,"median":-13.664169,"eighty":-6.151523,"high":-2.106753,"avg":-18.972919,"sd":15.673908,"marketCap":171625170},"quantilePoints":[{"date":"2024-03-01","current":-58.029616,"twenty":-57.969868,"median":-57.58151,"eighty":-55.109463,"marketCap":1279054027},{"date":"2024-03-08","current":-55.116932,"twenty":-57.969868,"median":-57.3948,"eighty":-55.049716,"marketCap":1214854404},{"date":"2024-03-15","current":-48.544723,"twenty":-57.715942,"median":-55.116932,"eighty":-49.664986,"marketCap":1069993717},{"date":"2024-03-22","current":-31.890149,"twenty":-57.596447,"median":-52.465643,"eighty":-44.108482,"marketCap":702903564},{"date":"2024-03-28","current":-25.919148,"twenty":-57.357457,"median":-49.38492,"eighty":-32.983824,"marketCap":571294337},{"date":"2024-04-05","current":-25.392625,"twenty":-55.998205,"median":-48.543977,"eighty":-28.607629,"marketCap":559689021},{"date":"2024-04-12","current":-18.446995,"twenty":-55.146806,"median":-35.064227,"eighty":-23.267262,"marketCap":406597612},{"date":"2024-04-19","current":-15.833048,"twenty":-54.915285,"median":-32.71989,"eighty":-19.118705,"marketCap":348982566},{"date":"2024-04-26","current":-6.348156,"twenty":-53.503754,"median":-29.329228,"eighty":-17.595595,"marketCap":139922255},{"date":"2024-05-03","current":-7.365355,"twenty":-52.428301,"median":-25.919148,"eighty":-15.026459,"marketCap":162342739},{"date":"2024-05-10","current":-2.698495,"twenty":-50.822591,"median":-23.061357,"eighty":-9.708944,"marketCap":163198734},{"date":"2024-05-17","current":-2.422494,"twenty":-49.291565,"median":-20.164731,"eighty":-7.316959,"marketCap":146506832},{"date":"2024-05-24","current":-2.231961,"twenty":-48.694091,"median":-18.372311,"eighty":-2.71254,"marketCap":134983822},{"date":"2024-05-31","current":-2.106753,"twenty":-48.544425,"median":-17.961548,"eighty":-2.656034,"marketCap":127411559},{"date":"2024-06-07","current":-8.033143,"twenty":-47.558444,"median":-17.550785,"eighty":-2.656034,"marketCap":148265257},{"date":"2024-06-14","current":-7.903098,"twenty":-44.108482,"median":-15.833048,"eighty":-2.68298,"marketCap":145865070},{"date":"2024-06-21","current":-6.795171,"twenty":-36.221832,"median":-12.47226,"eighty":-2.696046,"marketCap":125416385},{"date":"2024-06-28","current":-6.570165,"twenty":-35.295748,"median":-12.322891,"eighty":-2.697026,"marketCap":121263525},{"date":"2024-07-05","current":-6.173255,"twenty":-33.757254,"median":-8.033143,"eighty":-2.703177,"marketCap":113937879},{"date":"2024-07-12","current":-6.299258,"twenty":-33.071802,"median":-7.830197,"eighty":-2.721904,"marketCap":116263481},{"date":"2024-07-15","current":-6.435162,"twenty":-32.983824,"median":-7.830197,"eighty":-2.721904,"marketCap":118771808},{"date":"2024-08-02","current":-5.57114,"twenty":-32.895846,"median":-7.830197,"eighty":-2.721904,"marketCap":102824824},{"date":"2024-08-09","current":-5.526139,"twenty":-32.222045,"median":-7.468419,"eighty":-3.563104,"marketCap":101994252},{"date":"2024-08-16","current":-20.612899,"twenty":-30.545833,"median":-7.468046,"eighty":-4.127144,"marketCap":122353801},{"date":"2024-08-23","current":-17.275162,"twenty":-29.265149,"median":-7.830197,"eighty":-4.681198,"marketCap":102541700},{"date":"2024-08-30","current":-14.308285,"twenty":-28.407028,"median":-7.866648,"eighty":-5.281333,"marketCap":84930944},{"date":"2024-09-06","current":-12.936966,"twenty":-27.171154,"median":-9.617885,"eighty":-5.454137,"marketCap":76791088},{"date":"2024-09-13","current":-14.230663,"twenty":-25.708539,"median":-12.097501,"eighty":-5.499138,"marketCap":84470197},{"date":"2024-09-20","current":-12.649478,"twenty":-24.871927,"median":-12.454498,"eighty":-5.544139,"marketCap":75084620},{"date":"2024-09-27","current":-11.784139,"twenty":-23.267262,"median":-12.36199,"eighty":-5.658262,"marketCap":69948149},{"date":"2024-10-04","current":-8.756889,"twenty":-21.942215,"median":-12.240382,"eighty":-5.887588,"marketCap":51979034},{"date":"2024-10-11","current":-9.208245,"twenty":-21.329829,"median":-12.040003,"eighty":-6.069393,"marketCap":54658190},{"date":"2024-10-18","current":-39.673363,"twenty":-24.871927,"median":-12.127687,"eighty":-6.141394,"marketCap":235492672},{"date":"2024-10-25","current":-73.596963,"twenty":-29.393307,"median":-12.327491,"eighty":-6.173255,"marketCap":436855971},{"date":"2024-10-31","current":-70.722082,"twenty":-31.779361,"median":-12.436737,"eighty":-6.180635,"marketCap":419791285},{"date":"2024-11-08","current":-32.773648,"twenty":-33.757254,"median":-12.633666,"eighty":-6.224556,"marketCap":194537424},{"date":"2024-11-15","current":-42.548244,"twenty":-38.983392,"median":-12.936966,"eighty":-6.285578,"marketCap":252557358},{"date":"2024-11-22","current":-36.270609,"twenty":-39.155884,"median":-13.187081,"eighty":-6.299438,"marketCap":287084045},{"date":"2024-11-29","current":-28.972255,"twenty":-38.235922,"median":-13.602501,"eighty":-6.300158,"marketCap":229317133},{"date":"2024-12-06","current":-23.222036,"twenty":-37.373458,"median":-13.816575,"eighty":-6.348156,"marketCap":183803809},{"date":"2024-12-13","current":-22.337387,"twenty":-36.270609,"median":-14.269474,"eighty":-6.435162,"marketCap":176801759},{"date":"2024-12-20","current":-21.33331,"twenty":-36.221832,"median":-15.004006,"eighty":-6.508963,"marketCap":168854432},{"date":"2024-12-27","current":-23.222036,"twenty":-35.303209,"median":-15.833048,"eighty":-6.557925,"marketCap":183803809},{"date":"2025-01-03","current":-23.443198,"twenty":-34.373394,"median":-17.065337,"eighty":-6.580965,"marketCap":185554321},{"date":"2025-01-10","current":-28.52993,"twenty":-33.790638,"median":-17.550785,"eighty":-6.670967,"marketCap":225816108},{"date":"2025-01-17","current":-26.760632,"twenty":-33.439732,"median":-17.684618,"eighty":-6.873653,"marketCap":211812008},{"date":"2025-01-24","current":-30.52039,"twenty":-33.171426,"median":-18.032197,"eighty":-7.005548,"marketCap":241570720},{"date":"2025-01-31","current":-29.635741,"twenty":-33.528197,"median":-18.446995,"eighty":-7.075423,"marketCap":234568670},{"date":"2025-02-07","current":-31.405039,"twenty":-33.171426,"median":-19.295444,"eighty":-7.138439,"marketCap":248572770},{"date":"2025-02-14","current":-34.501311,"twenty":-33.892862,"median":-20.164731,"eighty":-7.192457,"marketCap":273079945},{"date":"2025-02-21","current":-34.280148,"twenty":-34.280148,"median":-20.612899,"eighty":-7.244366,"marketCap":271329432},{"date":"2025-02-28","current":-27.645281,"twenty":-34.280148,"median":-21.570546,"eighty":-7.365355,"marketCap":218814058},{"date":"2025-03-07","current":-24.327847,"twenty":-34.058986,"median":-22.031836,"eighty":-7.370735,"marketCap":192556371},{"date":"2025-03-14","current":-24.54901,"twenty":-33.906622,"median":-22.226806,"eighty":-7.443187,"marketCap":194306884},{"date":"2025-03-21","current":-25.875983,"twenty":-33.837824,"median":-22.558549,"eighty":-7.452187,"marketCap":204809958},{"date":"2025-03-28","current":-26.53947,"twenty":-33.616662,"median":-23.000874,"eighty":-7.454567,"marketCap":210061496},{"date":"2025-04-04","current":-13.396106,"twenty":-33.174337,"median":-23.222036,"eighty":-7.467672,"marketCap":183893433},{"date":"2025-04-11","current":-13.396106,"twenty":-33.15978,"median":-22.669131,"eighty":-7.468419,"marketCap":183893433},{"date":"2025-04-17","current":-13.664028,"twenty":-32.994496,"median":-22.447968,"eighty":-7.468419,"marketCap":187571301},{"date":"2025-04-25","current":-13.530067,"twenty":-32.809553,"median":-22.063146,"eighty":-7.757841,"marketCap":185732367},{"date":"2025-05-02","current":-13.10675,"twenty":-32.74034,"median":-21.917772,"eighty":-7.830197,"marketCap":179921334},{"date":"2025-05-09","current":-14.601755,"twenty":-32.722315,"median":-21.231576,"eighty":-7.830197,"marketCap":200443841},{"date":"2025-05-16","current":-5.980818,"twenty":-32.552659,"median":-20.228412,"eighty":-7.830197,"marketCap":211477447},{"date":"2025-05-23","current":-6.396875,"twenty":-32.510851,"median":-19.566511,"eighty":-7.465051,"marketCap":226188922},{"date":"2025-05-30","current":-6.968954,"twenty":-32.378153,"median":-18.686729,"eighty":-7.414206,"marketCap":246417200},{"date":"2025-06-06","current":-7.333003,"twenty":-32.156991,"median":-18.297627,"eighty":-7.218412,"marketCap":259289740},{"date":"2025-06-13","current":-6.604904,"twenty":-32.068526,"median":-17.743768,"eighty":-7.033891,"marketCap":233544659},{"date":"2025-06-20","current":-6.240854,"twenty":-31.997175,"median":-17.550785,"eighty":-6.875341,"marketCap":220672119},{"date":"2025-06-27","current":-6.155194,"twenty":-31.696105,"median":-17.17025,"eighty":-6.729721,"marketCap":217643250},{"date":"2025-07-03","current":-6.46817,"twenty":-31.405039,"median":-16.307839,"eighty":-6.667312,"marketCap":228709856},{"date":"2025-07-11","current":-6.682997,"twenty":-31.405039,"median":-15.62498,"eighty":-6.591513,"marketCap":236305988},{"date":"2025-07-18","current":-6.792554,"twenty":-31.391273,"median":-15.003822,"eighty":-6.576385,"marketCap":240179856},{"date":"2025-07-25","current":-5.861317,"twenty":-31.327857,"median":-14.601755,"eighty":-6.518995,"marketCap":207251973},{"date":"2025-08-01","current":-5.419253,"twenty":-31.139644,"median":-14.400813,"eighty":-6.46817,"marketCap":191620913},{"date":"2025-08-08","current":-4.760814,"twenty":-30.52039,"median":-14.230663,"eighty":-6.437906,"marketCap":168338962},{"date":"2025-08-15","current":-6.178593,"twenty":-30.431925,"median":-14.065911,"eighty":-6.351294,"marketCap":192770965},{"date":"2025-08-22","current":-5.701959,"twenty":-30.042206,"median":-13.93195,"eighty":-6.299316,"marketCap":177900062},{"date":"2025-08-29","current":-5.69061,"twenty":-29.890394,"median":-13.807282,"eighty":-6.244587,"marketCap":177545993},{"date":"2025-09-05","current":-5.543711,"twenty":-29.856904,"median":-13.784336,"eighty":-6.173255,"marketCap":172962765},{"date":"2025-09-11","current":-5.500839,"twenty":-29.856904,"median":-13.664169,"eighty":-6.151523,"marketCap":171625170}],"updateTime":1757699650306},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566983519","title":"Tevogen Bio Holdings Inc.'s CIO to Join Panel at Databricks DATA + AI World Tour in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2566983519","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566983519?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:59","pubTimestamp":1757519953,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. Mehta will discuss Tevogen.AI's application of advanced data and AI technologies, including its PredicTcell platform, developed in collaboration with Microsoft and Databricks, to accelerate precision immunotherapy development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL64lwBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1145028129.USD","LU0683600562.USD","IE00BQXX3F31.USD","TVGN","LU1674673691.USD","IE0034235303.USD","LU1153585028.USD","LU0154236417.USD","IE00BQXX3C00.GBP","LU0738911758.USD","LU2168564222.USD","LU2168564495.EUR","LU0661504455.SGD","LU1868837136.USD","LU0861579265.USD","IE00B3QW5Z07.USD","BK4612","LU2347655073.USD","SG9999017495.SGD","LU2247934214.USD","LU0096364046.USD","NDAQ","LU0757359954.USD","IE00B7KXQ091.USD","IE00B775H168.HKD","LU0072461881.USD","IE00BKVL7J92.USD","LU2092937221.SGD","LU1564329032.USD","LU0256863902.USD","IE00B64PRP62.GBP","IE00BJJMRY28.SGD","LU1868837300.USD","LU0061475181.USD","LU0316494557.USD","LU0238689110.USD","LU0061474960.USD","LU1670711123.USD","LU0426412945.USD","IE00BMPRXQ63.HKD","LU2092627202.USD","LU0894486033.HKD","IE000ITXATA3.USD","LU0323239441.USD","IE00B5949003.HKD","LU0466842654.USD","LU0949170426.SGD","LU1267930813.SGD","SG9999018865.SGD"],"gpt_icon":1},{"id":"2566835629","title":"Tevogen Cio and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks Data + AI World Tour in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2566835629","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566835629?lang=en_us&edition=fundamental","pubTime":"2025-09-10 23:59","pubTimestamp":1757519942,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nTUA3KBB6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":0},{"id":"2566610359","title":"Tevogen Bio Holdings Inc - Tvgn 116 Cumulative 5-Year Top-Line Revenue Forecast Is Estimated to Be About $6.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2566610359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566610359?lang=en_us&edition=fundamental","pubTime":"2025-09-10 03:17","pubTimestamp":1757445446,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nFWN3UW0NU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2566610355","title":"Tevogen Bio Projects $6.5 Billion in Revenue Over 5 Years for Liver Cancer Prevention Product, TVGN 116","url":"https://stock-news.laohu8.com/highlight/detail?id=2566610355","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566610355?lang=en_us&edition=fundamental","pubTime":"2025-09-10 03:15","pubTimestamp":1757445317,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc., listed on Nasdaq as TVGN, has disclosed financial projections for its pipeline product, TVGN 116, aimed at preventing liver cancer in patients with high-risk chronic Hepatitis B infections. The company estimates a cumulative 5-year top-line revenue of approximately $6.5 billion, highlighting its innovative approach to drug development that emphasizes speed and cost-efficiency. Additionally, the risk-adjusted Net Present Value  for TVGN 116 is projected to exceed $325 million in the United States alone, indicating significant potential in addressing unmet medical needs within the competitive landscape. Tevogen's rapid progress with its clinical-stage product, TVGN 489, underscores the company's capability to achieve necessary milestones swiftly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL5q5GZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","NDAQ"],"gpt_icon":0},{"id":"2565768233","title":"Tevogen Bio Holdings Inc - Values Tvgn-489 at $9-$11 Bln Risk-Adjusted Net Present Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2565768233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565768233?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:28","pubTimestamp":1757338105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nFWN3UV1E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":0},{"id":"2565682338","title":"Tevogen Bio Announces $9-11 Billion Valuation for TVGN-489, Highlighting Promising Phase I Clinical Trial Results for COVID-19 Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2565682338","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565682338?lang=en_us&edition=fundamental","pubTime":"2025-09-08 21:27","pubTimestamp":1757338079,"startTime":"0","endTime":"0","summary":"Tevogen Bio Announces $9-11 Billion Valuation for TVGN-489, Highlighting Promising Phase I Clinical Trial Results for COVID-19 Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL2gHwzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4585","BK4139","LU2210150020.SGD","BK4112","BK4588","IE00BGHQF748.EUR","TVGN","LU2095319765.USD","IE00B64PRP62.GBP","LU0314104364.USD"],"gpt_icon":0},{"id":"2565964307","title":"Tevogen Bio Projects $3.5 Billion Revenue Over 5 Years, Highlights $250 Million rNPV for Key Asset TVGN 930","url":"https://stock-news.laohu8.com/highlight/detail?id=2565964307","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565964307?lang=en_us&edition=fundamental","pubTime":"2025-09-05 03:48","pubTimestamp":1757015325,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL3bqDSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","NDAQ"],"gpt_icon":0},{"id":"2564796383","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2564796383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564796383?lang=en_us&edition=fundamental","pubTime":"2025-09-04 19:21","pubTimestamp":1756984860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 04, 2025 07:21 ET (11:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2564177319","title":"Tevogen Bio Announces Promising Clinical Trial Results for TVGN 489, Aiming to Enhance COVID-19 Immunotherapy for Vulnerable Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2564177319","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564177319?lang=en_us&edition=fundamental","pubTime":"2025-09-04 04:15","pubTimestamp":1756930529,"startTime":"0","endTime":"0","summary":"Tevogen Bio Announces Promising Clinical Trial Results for TVGN 489, Aiming to Enhance COVID-19 Immunotherapy for Vulnerable Populations. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on September 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL4wkkcQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","BK4112","LU2095319765.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","TVGN","LU2210149790.SGD","BK4585","NDAQ","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2560311464","title":"Tevogen Bio Holdings: Enters Into Agreement for up to $50 Mln in Financing to Advance R&D and Clinical Development Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2560311464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560311464?lang=en_us&edition=fundamental","pubTime":"2025-08-20 03:42","pubTimestamp":1755632521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nFWN3UB0RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2560534114","title":"Press Release: REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2560534114","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560534114?lang=en_us&edition=fundamental","pubTime":"2025-08-20 03:40","pubTimestamp":1755632400,"startTime":"0","endTime":"0","summary":"-- Includes $36 million line of credit and potential $14 million private. The private placement is available at the counterparty's option after the trailing 10-day volume weighted average share price reaches $10 per share and would be priced at a 30% discount to that price. The private placement can also include any remaining available and undrawn amount of the line of credit.Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainabi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4139","BK4588","TVGN","TM","03160","BK4585","BK4555","BK4604"],"gpt_icon":0},{"id":"2560115444","title":"BRIEF-Tevogen Bio Holdings Anticipates Revenue By End Of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2560115444","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560115444?lang=en_us&edition=fundamental","pubTime":"2025-08-20 00:29","pubTimestamp":1755620997,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Holdings Anticipates Revenue By End Of 2026Aug 19 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO HOLDINGS INC - ANTICIPATES REVENUE BY END OF 2026Source text: ID:nGNX6sSQhdFurther company coverage: TVGN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nFWN3UB02R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0},{"id":"2560592115","title":"Tevogen Bio Holdings Inc - Anticipates Revenue by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2560592115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560592115?lang=en_us&edition=fundamental","pubTime":"2025-08-20 00:12","pubTimestamp":1755619964,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nFWN3UB02R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2560115530","title":"Tevogen Bio Holdings Reports Reduced Q2 2025 Net Loss of $5.5M, Down from $9.7M in Q2 2024, as Operating Efficiency Improves","url":"https://stock-news.laohu8.com/highlight/detail?id=2560115530","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560115530?lang=en_us&edition=fundamental","pubTime":"2025-08-20 00:10","pubTimestamp":1755619813,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings Inc. reported a reduction in its operational losses for the second quarter of 2025. The company announced a loss from operations of $5.4 million for the quarter ended June 30, 2025, a notable improvement compared to the $8.6 million loss reported for the same period in 2024. The net loss for the quarter was $5.5 million, down from $9.7 million in the second quarter of 2024. Tevogen continues to focus on maximizing capital efficiency and has maintained access to financing to support its growth strategies. The company is advancing its infrastructure, artificial intelligence capabilities, and internal strengths in a market experiencing limited growth. It also anticipates generating revenue by the end of 2026 and is actively exploring options to address its limited tradable float to better meet investor demand. In a strategic move, Tevogen is in the process of establishing its own GMP manufacturing facility, which aims to enhance control over its production processes a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL2k0cgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","NDAQ"],"gpt_icon":0},{"id":"2560211534","title":"Press Release: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2560211534","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560211534?lang=en_us&edition=fundamental","pubTime":"2025-08-20 00:10","pubTimestamp":1755619800,"startTime":"0","endTime":"0","summary":"-- Expenses significantly lower with expansion on multiple efforts; Q2 2025. loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.-- Tevogen maximizes capital efficiency, maintains access to financing to. support growth, and anticipates revenue by end of 2026; Exploring options. -- Building infrastructure, advancing AI, and expanding internal. \"In our sector, it is common to see companies incur significantly larger operating losses than Tevogen, yet at Tevogen, every dollar goes a long way as we continue building infrastructure, advancing AI, and strengthening internal capabilities in a market that is otherwise seeing limited growth. We also maintain access to sufficient capital to support our path to anticipated revenue by the end of 2026. At the same time, we recognize that our current limited tradable float does not fully meet investor demand, and we are actively exploring options to address this.\" said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"gpt_icon":0},{"id":"2560364541","title":"Press Release: Tevogen CEO Donates Personal Shares to Support Local Law Enforcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2560364541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560364541?lang=en_us&edition=fundamental","pubTime":"2025-08-19 05:50","pubTimestamp":1755553800,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Aug. 18, 2025  -- Tevogen  , today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his personal shares of common stock to the Warren Township Honorary Policemen's Benevolent Association  Local 235.The Warren Township P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contributes to the D.A.R.E. and Explorer programs, provides assistance to families of fallen and injured police officers, and works to foster a strong relationship with Warren Township residents as well as P.B.A. Locals across New Jersey.Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2560772135","title":"Press Release: Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2560772135","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560772135?lang=en_us&edition=fundamental","pubTime":"2025-08-19 05:15","pubTimestamp":1755551700,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Aug. 18, 2025  -- Tevogen  , today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.--based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self--esteem, and community reintegration.Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"gpt_icon":0},{"id":"2560044029","title":"Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2560044029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560044029?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:41","pubTimestamp":1755517260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TVGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 07:41 ET (11:41 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}